Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001636282-25-000024
Filing Date
2025-02-27
Accepted
2025-02-27 16:13:44
Documents
16
Effectiveness Date
2025-02-27

Document Format Files

Seq Description Document Type Size
1 S-8 spyre-february2025xsx8.htm S-8 61306
2 EX-23.1 ex231pwcs-8consent.htm EX-23.1 2010
3 EX-5.1 ex51-gibsonopinion.htm EX-5.1 12317
4 gdclogo.jpg GRAPHIC 16094
5 EX-FILING FEES exfilingfees.htm   iXBRL EX-FILING FEES 45744
  Complete submission text file 0001636282-25-000024.txt   273657

Data Files

Seq Description Document Type Size
18 EXTRACTED XBRL INSTANCE DOCUMENT exfilingfees_htm.xml XML 4507
Mailing Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453 6176515940
Spyre Therapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-285332 | Film No.: 25678928
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)